Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sujoy Mukherjee

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
The Journal of Biological Chemistry|November 27, 2009
Activator Gcn4 employs multiple segments of Med15/Gal11, including the KIX domain, to recruit mediator to target genes in vivoIness Jedidi, Fan Zhang, Hongfang Qiu, et al.
Oncology and Therapy|September 4, 2025
Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung CancerMyung-Ju Ahn, Byoung Chul Cho, Kadoaki Ohashi, et al.
Advances in Therapy|March 2, 2025
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 TrialHorst-Dieter Hummel, Myung-Ju Ahn, Fiona Blackhall, et al.
Cancer|January 29, 2025
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancerJacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, et al.
Journal of the American Chemical Society|March 25, 2009
Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigationYonghui Zhang, Rong Cao, Fenglin Yin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2023
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I StudyLuis Paz-Ares, Stephane Champiat, W Victoria Lai, et al.
Future Oncology (London, England)|November 12, 2024
Plain language summary: tarlatamab for patients with previously treated small cell lung cancerMyung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, et al.
The New England Journal of Medicine|October 20, 2023
Tarlatamab for Patients with Previously Treated Small-Cell Lung CancerMyung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
The Journal of Biological Chemistry|November 27, 2009
Activator Gcn4 employs multiple segments of Med15/Gal11, including the KIX domain, to recruit mediator to target genes in vivoIness Jedidi, Fan Zhang, Hongfang Qiu, et al.
Oncology and Therapy|September 4, 2025
Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung CancerMyung-Ju Ahn, Byoung Chul Cho, Kadoaki Ohashi, et al.
Advances in Therapy|March 2, 2025
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 TrialHorst-Dieter Hummel, Myung-Ju Ahn, Fiona Blackhall, et al.
Cancer|January 29, 2025
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancerJacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, et al.
Journal of the American Chemical Society|March 25, 2009
Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigationYonghui Zhang, Rong Cao, Fenglin Yin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2023
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I StudyLuis Paz-Ares, Stephane Champiat, W Victoria Lai, et al.
Future Oncology (London, England)|November 12, 2024
Plain language summary: tarlatamab for patients with previously treated small cell lung cancerMyung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, et al.
The New England Journal of Medicine|October 20, 2023
Tarlatamab for Patients with Previously Treated Small-Cell Lung CancerMyung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, et al.
Pageof 5